放射性标记FAPIs在非恶性病变中的临床应用  

Clinical application of radiolabeled FAPIs in non-malignant lesions

作　　者：王玺[1] 韩巍[1] 吕哲昊 刘珊[1] 王延 付鹏[1] Wang Xi;Han Wei;Lyu Zhehao;Liu Shan;Wang Yan;Fu Peng(Department of Nuclear Medicine,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院核医学科,哈尔滨150001

出　　处：《中华核医学与分子影像杂志》2024年第1期51-55,共5页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：黑龙江省省属高等学校基本科研业务费科研项目(2022-KYYWF-0266);哈医大一院科研创新基金(2021M16)。

摘　　要：成纤维细胞激活蛋白抑制剂(FAPI)自问世以来一直是核医学界的关注热点。随着FAPI示踪剂的深入研究, 其在各种非恶性病变中的临床应用也被逐渐报道, 已有多项研究证实其在多种非恶性病变中有摄取, 具有良好的应用前景。该文就放射性标记的FAPIs在国内外包括心血管疾病、风湿免疫性疾病、免疫球蛋白(Ig)G4相关疾病、肾纤维化及其他非恶性病变中的最新研究现状及临床应用进行综述总结。Fibroblast activation protein inhibitor(FAPI)has been the focus of nuclear medicine since its introduction.With the in-depth study of FAPI tracer,its clinical application in various non-malignant diseases has also been gradually reported.Many studies have confirmed its uptake in a variety of non-malignant diseases,which indicate that FAPI tracers have good application prospects.This article reviews the latest research status and clinical application of radiolabeled FAPIs in cardiovascular diseases,rheumatic immune diseases,immunoglobulin(Ig)G4-related diseases,renal fibrosis and other non-malignant diseases at home and abroad.

关 键 词：拮抗剂和抑制剂 膜蛋白质类 成纤维细胞 发展趋势 

分 类 号：R817[医药卫生—影像医学与核医学]